X-101397549-C-T

Variant summary

Our verdict is Benign. The variant received -14 ACMG points: 0P and 14B. BP4_StrongBP6_ModerateBS1BS2

The ENST00000409170.3(RPL36A-HNRNPH2):​c.300+2092C>T variant causes a intron change involving the alteration of a non-conserved nucleotide. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★).

Frequency

Genomes: 𝑓 0.0083 ( 7 hom., 155 hem., cov: 20)

Consequence

RPL36A-HNRNPH2
ENST00000409170.3 intron

Scores

2

Clinical Significance

Likely benign criteria provided, single submitter B:1

Conservation

PhyloP100: -3.08

Publications

0 publications found
Variant links:
Genes affected
RPL36A-HNRNPH2 (HGNC:48349): (RPL36A-HNRNPH2 readthrough) This locus represents naturally occurring read-through transcription between the neighboring ribosomal protein L36a and heterogeneous nuclear ribonucleoprotein H2 (H') genes on chromosome X. The read-through transcript produces a protein with similarity to the protein encoded by the upstream locus, ribosomal protein L36a. Alternatively spliced transcript variants have been identified. [provided by RefSeq, Jan 2011]
GLA (HGNC:4296): (galactosidase alpha) This gene encodes a homodimeric glycoprotein that hydrolyses the terminal alpha-galactosyl moieties from glycolipids and glycoproteins. This enzyme predominantly hydrolyzes ceramide trihexoside, and it can catalyze the hydrolysis of melibiose into galactose and glucose. A variety of mutations in this gene affect the synthesis, processing, and stability of this enzyme, which causes Fabry disease, a rare lysosomal storage disorder that results from a failure to catabolize alpha-D-galactosyl glycolipid moieties. [provided by RefSeq, Jul 2008]
GLA Gene-Disease associations (from GenCC):
  • Fabry disease
    Inheritance: XL Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Genomics England PanelApp, ClinGen, Orphanet, G2P, Labcorp Genetics (formerly Invitae)

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -14 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.97).
BP6
Variant X-101397549-C-T is Benign according to our data. Variant chrX-101397549-C-T is described in ClinVar as [Likely_benign]. Clinvar id is 1202191.Status of the report is criteria_provided_single_submitter, 1 stars.
BS1
Variant frequency is greater than expected in population afr. GnomAd4 allele frequency = 0.00829 (789/95171) while in subpopulation AFR AF = 0.0383 (752/19641). AF 95% confidence interval is 0.036. There are 7 homozygotes in GnomAd4. There are 155 alleles in the male GnomAd4 subpopulation. Median coverage is 20. This position passed quality control check.
BS2
High Homozygotes in GnomAd4 at 7 gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
RPL36A-HNRNPH2NM_001199973.2 linkc.300+2092C>T intron_variant Intron 4 of 4 NP_001186902.2
RPL36A-HNRNPH2NM_001199974.2 linkc.177+5727C>T intron_variant Intron 3 of 3 NP_001186903.2

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
RPL36A-HNRNPH2ENST00000409170.3 linkc.300+2092C>T intron_variant Intron 4 of 4 4 ENSP00000386655.4 H7BZ11

Frequencies

GnomAD3 genomes
AF:
0.00827
AC:
787
AN:
95150
Hom.:
7
Cov.:
20
show subpopulations
Gnomad AFR
AF:
0.0383
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00277
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.0146
Gnomad NFE
AF:
0.0000390
Gnomad OTH
AF:
0.00536
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome
AF:
0.00829
AC:
789
AN:
95171
Hom.:
7
Cov.:
20
AF XY:
0.00635
AC XY:
155
AN XY:
24417
show subpopulations
African (AFR)
AF:
0.0383
AC:
752
AN:
19641
American (AMR)
AF:
0.00277
AC:
25
AN:
9026
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
2584
East Asian (EAS)
AF:
0.00
AC:
0
AN:
3256
South Asian (SAS)
AF:
0.00
AC:
0
AN:
2073
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
5087
Middle Eastern (MID)
AF:
0.0155
AC:
3
AN:
193
European-Non Finnish (NFE)
AF:
0.0000390
AC:
2
AN:
51331
Other (OTH)
AF:
0.00529
AC:
7
AN:
1323
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.506
Heterozygous variant carriers
0
32
64
97
129
161
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
20
40
60
80
100
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.00
Hom.:
0

ClinVar

Significance: Likely benign
Submissions summary: Benign:1
Revision: criteria provided, single submitter
LINK: link

Submissions by phenotype

not provided Benign:1
Jul 27, 2018
GeneDx
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.97
CADD
Benign
0.52
DANN
Benign
0.61
PhyloP100
-3.1

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs140006150; hg19: chrX-100652537; API